Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer

Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer

Abstract Background HER2-targeted antibody–drug conjugates (ADCs) have revolutionized the treatment landscape of metastatic breast cancer. However, the efficacy of these therapies may be compromised by genomic alterations. Hence, this study aims to identify factors predicting sensitivity to HER2 ADC...

Full description

Saved in:
Bibliographic Details
Main Authors: Riqing Huang, Anqi Hu, Qixiang Rong, Ditian Shu, Meiting Chen, Wei Yang, Yue Zhang, Qiufan Zheng, Xin An, Cong Xue, Haifeng Li, Yanxia Shi
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Journal of Translational Medicine
Subjects:
Breast cancer
Antibody–drug conjugate
Cell cycle
CDK12
Online Access:https://doi.org/10.1186/s12967-025-06082-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12967-025-06082-5

Similar Items